TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31382028

Group type: EXPERIMENTAL
Intervention: Compression wire arthrodesis (n=8)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intraosseous wiring arthrodesis (n=9)
Number of subjects: 17
Study: 28808808

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (modified Atkins diet)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Gluten free casein free diet (GFCF)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Balanced nutrition (control group)
Number of subjects: 45
Study: 25280429

Group type: EXPERIMENTAL
Intervention: Lurasidone (40-160 mg/d)
Number of subjects: 1029
Study: 23438101

Group type: EXPERIMENTAL
Intervention: 1.8 g of omega-3 polyunsaturated fatty acids (PUFA) for 12 weeks
Number of subjects: 201

Group type: COMPARATOR
Intervention: 500 mg of metformin (Met) for 12 weeks
Number of subjects: 201
Study: 21692897

Group type: COMPARATOR
Intervention: PVAI alone (group I)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: PVAI plus CFAE ablation (group II)
Number of subjects: 98
Study: 18431350

Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circulation with low dose systemic heparin (Group C)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circulation with conventional dose systemic heparin (Group B)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Uncoated extracorporeal circulation with conventional dose systemic heparin (Group A)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits and low dose systemic heparin
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits with conventional dose systemic heparin
Number of subjects: 450
Study: 17060116

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 51

Group type: COMPARATOR
Intervention: Losartan and Atenolol
Number of subjects: 51
Study: 12440653

Group type: EXPERIMENTAL
Intervention: CD-ROM Internet Hybrid curriculum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional textbook-based learning
Number of subjects: 0
Study: 10071998

Group type: EXPERIMENTAL
Intervention: Fentanyl (10 microg) added to 1.5% lidocaine (45 mg hyperbaric)
Number of subjects: 78

Group type: COMPARATOR
Intervention: 1.5% lidocaine (45 mg hyperbaric) alone
Number of subjects: 78
Study: 7706761

Group type: EXPERIMENTAL
Intervention: Single UV exposure with double the patient's minimal erythema dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonirradiated, shielded half of the same nevus
Number of subjects: 0
Study: 2341229

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) - 400 kcal/day for 8 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Balanced Deficit Diet (BDD) - 1200 kcal/day for 18 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 15
Study: 7441622

Group type: EXPERIMENTAL
Intervention: Detailed information about the study; 568 practitioners; 19.7% agreed to participate.
Number of subjects: 1176

Group type: COMPARATOR
Intervention: Brief introduction to the study; 605 practitioners; 33.4% agreed to participate.
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: Weekly reminders sent to two thirds of the doctors; remaining third did not receive reminders.
Number of subjects: 1176
Study: 6094282

Group type: EXPERIMENTAL
Intervention: Topical tioconazole 6% vaginal ointment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Systemic ketoconazole (400 mg/day for 5 days)
Number of subjects: 40
Study: 30560523

Group type: EXPERIMENTAL
Intervention: Positive reinforcement technique with awards after dental care (G2)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 306
Study: 29337023

Group type: EXPERIMENTAL
Intervention: Functional training (n=22)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bicycle exercise (n=20)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Exergaming (n=20)
Number of subjects: 62
Study: 27555197

Group type: EXPERIMENTAL
Intervention: Caudal dexmedetomidine (1 μg/kg) with caudal bupivacaine
Number of subjects: 75

Group type: COMPARATOR
Intervention: IV dexmedetomidine (1 μg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: IV saline (control group)
Number of subjects: 75
Study: 25001159

Group type: EXPERIMENTAL
Intervention: Ranibizumab intravitreal administration
Number of subjects: 876
Study: 22585883

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring, weekly health coaching, and home titration of blood pressure medications (n = 129)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Home blood pressure monitoring and health coaching but no home titration (n = 108)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Combined analysis of both arms
Number of subjects: 237
Study: 19816218

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) exercise at 30 Hz and 3.5 mm amplitude
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham group (S) performing the same exercises without vibration
Number of subjects: 19
Study: 17567564

Group type: EXPERIMENTAL
Intervention: Telephone follow-up survey
Number of subjects: 700

Group type: COMPARATOR
Intervention: Mail follow-up survey
Number of subjects: 700
Study: 15615747

Group type: EXPERIMENTAL
Intervention: Expedited cataract surgery (approximately 4 weeks wait)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Routine cataract surgery (12 months wait)
Number of subjects: 306
Study: 11826591

Group type: EXPERIMENTAL
Intervention: Diacerein
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10068173

Group type: EXPERIMENTAL
Intervention: Chronic pain grade (CPG) measured by SF36 and Glasgow Pain Questionnaire
Number of subjects: 5036

Group type: EXPERIMENTAL
Intervention: Chronic pain management addressing social and psychological well-being
Number of subjects: 5036
Study: 7598089

Group type: EXPERIMENTAL
Intervention: Qigong training for more than 5 months
Number of subjects: 0
Study: 2401751

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg bid
Number of subjects: 10

Group type: COMPARATOR
Intervention: Warfarin sodium 30 mg
Number of subjects: 10
Study: 7004446

Group type: EXPERIMENTAL
Intervention: multivalent pneumococcal polysaccharide vaccine
Number of subjects: 32

Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 32
Study: 31574047

Group type: EXPERIMENTAL
Intervention: Fractionated CO2 vaginal laser therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Vaginal estrogen cream
Number of subjects: 69
Study: 31117729

Group type: EXPERIMENTAL
Intervention: DNA/AuNPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selection process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binding experiments with synthetic DNA oligonucleotides
Number of subjects: 0
Study: 30006390

Group type: EXPERIMENTAL
Intervention: BLISS (baby-led weaning)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control (traditional spoon-feeding)
Number of subjects: 206
Study: 27323792

Group type: EXPERIMENTAL
Intervention: Office visit intervention
Number of subjects: 489

Group type: COMPARATOR
Intervention: Patient portal intervention
Number of subjects: 489
Study: 25085017

Group type: EXPERIMENTAL
Intervention: Amino acids only (Group A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Amino acids and glucose (Group AG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Neither amino acids nor glucose (Group C)
Number of subjects: 21
Study: 22079554

Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 9193

Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 9193

Group type: COMPARATOR
Intervention: Black race
Number of subjects: 9193
Study: 21171669

Group type: EXPERIMENTAL
Intervention: Etamicastat 25, 50, 100, 200, 400, or 600 mg once daily for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etamicastat
Number of subjects: 0
Study: 17924869

Group type: EXPERIMENTAL
Intervention: Fenofibrate 80 mg + Metformin 850 mg
Number of subjects: 681

Group type: COMPARATOR
Intervention: Fenofibrate 80 mg
Number of subjects: 681

Group type: COMPARATOR
Intervention: Metformin 850 mg
Number of subjects: 681
Study: 15661836

Group type: EXPERIMENTAL
Intervention: Tilt angle at 47 degrees
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tilt angle at 90 degrees
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tilt angle at 32 degrees
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tilt angle at 47 degrees (constant-force test)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tilt angle at 67 degrees (constant-force test)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nonischemic exercise in inclined position
Number of subjects: 19

Group type: COMPARATOR
Intervention: Graded or constant-force exercise with arterial flow eliminated
Number of subjects: 19
Study: 14631587

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with standardized allergenic extracts, starting with 0.07 bioequivalent units (BEU), increasing to a maintenance dose of 700 BEU at six months, applied twice a week.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Pharmacological treatment only (Control group).
Number of subjects: 54
Study: 10624642

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.09 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.14 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.19 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.01 mg/kg (priming dose)
Number of subjects: 60
Study: 7770402

Group type: EXPERIMENTAL
Intervention: Calcium nadroparin (0.3 ml daily, 3075 anti-Xa IU)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Calcium heparin (0.2 ml-5000 UI if bodyweight < 70 kg or 0.3 ml-7500 IU if bodyweight ≥ 70 kg, twice a day)
Number of subjects: 295
Study: 2391575

Group type: EXPERIMENTAL
Intervention: REC group (resistive exercise circuit)
Number of subjects: 43

Group type: COMPARATOR
Intervention: WT group (standard weight training and running)
Number of subjects: 43
Study: 6907498

Group type: EXPERIMENTAL
Intervention: New foot supports
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metal stirrups
Number of subjects: 100
Study: 30195178

Group type: EXPERIMENTAL
Intervention: 15 min of jogging at 'moderate' intensity
Number of subjects: 101

Group type: COMPARATOR
Intervention: 15 min of relaxation/concentration (control condition)
Number of subjects: 101
Study: 27080865

Group type: EXPERIMENTAL
Intervention: Relay Model intervention group
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual procedures control group
Number of subjects: 500
Study: 25470694

Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg twice daily)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed plus cisplatin or carboplatin)
Number of subjects: 343
Study: 22130391

Group type: EXPERIMENTAL
Intervention: RE_L (Resistance Exercise at 23% of 1RM)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: RE_M (Resistance Exercise at 43% of 1RM)
Number of subjects: 19

Group type: COMPARATOR
Intervention: CON (Control session)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: RE_L (Resistance Exercise at 23% of 1RM) for ND
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: RE_M (Resistance Exercise at 43% of 1RM) for ND
Number of subjects: 19

Group type: COMPARATOR
Intervention: CON (Control session) for ND
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: RE_M (Resistance Exercise at 43% of 1RM) for T2D
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: RE_L (Resistance Exercise at 23% of 1RM) for T2D
Number of subjects: 19

Group type: COMPARATOR
Intervention: CON (Control session) for T2D
Number of subjects: 19
Study: 20662912

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate solution rinse for 60 seconds after exposure to hydrochloric acid (0.01 M, pH 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deionized water rinse for 60 seconds after exposure to hydrochloric acid (0.01 M, pH 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate solution rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deionized water rinse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both rinses (sodium bicarbonate and deionized water)
Number of subjects: 0
Study: 17971401

Group type: EXPERIMENTAL
Intervention: Presence of functional mitral regurgitation (MR)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Absence of functional mitral regurgitation (MR)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Functional mitral regurgitation (MR)
Number of subjects: 279
Study: 15968470

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 81

Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 81

Group type: COMPARATOR
Intervention: Isoflurane and Propofol anesthesia
Number of subjects: 81
Study: 12467132

Group type: EXPERIMENTAL
Intervention: 1 g of calcium + placebo
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 30 g of amylomaize (19 g of resistant starch) + placebo
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 9825167

Group type: EXPERIMENTAL
Intervention: Desensitization exercises with dilators (in vivo)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Desensitization exercises with dilators (in vitro)
Number of subjects: 44
Study: 7988310

Group type: EXPERIMENTAL
Intervention: Traditional lifestyle (Mexican Pimas)
Number of subjects: 35
Study: 2728951

Group type: EXPERIMENTAL
Intervention: Contingent payment/frequent monitoring (n = 17)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Noncontingent payment/frequent monitoring (n = 16)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Non‐contingent payment/infrequent monitoring (n = 14)
Number of subjects: 47
Study: 27618789

Group type: EXPERIMENTAL
Intervention: Early detection plus integrated care (n=120)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Standard care (SC, n=105)
Number of subjects: 225
Study: 26406164

Group type: EXPERIMENTAL
Intervention: Genomic information
Number of subjects: 201

Group type: COMPARATOR
Intervention: Behavioral information
Number of subjects: 201
Study: 24275006

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 18
Study: 22795519

Group type: EXPERIMENTAL
Intervention: MDRD‐4 GFR
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Serum creatinine levels
Number of subjects: 188

Group type: COMPARATOR
Intervention: Classical cardiovascular risk factors
Number of subjects: 188
Study: 21275162

Group type: EXPERIMENTAL
Intervention: Huatan Tongluo Granule (HTG)
Number of subjects: 66
Study: 18165460

Group type: EXPERIMENTAL
Intervention: Paliperidone ER (3-12 mg/day)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 15745936

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ethinyl estradiol-cyproterone acetate
Number of subjects: 35
Study: 14746003

Group type: EXPERIMENTAL
Intervention: Lead isotope ratios from blood specimens
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lead isotope ratios from leaded gasoline
Number of subjects: 16
Study: 10397416

Group type: EXPERIMENTAL
Intervention: Neuroleptic drug therapy
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: First-episode-psychosis patients
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study: 9163067

Group type: EXPERIMENTAL
Intervention: IBD patients (CD and UC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 100
Study: 8219952

Group type: EXPERIMENTAL
Intervention: Near patient testing for biochemical and bacteriological tests
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no near patient testing)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Near patient testing for midstream urine analysis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Near patient testing for cholesterol tests
Number of subjects: 12
Study: 2956958

Group type: COMPARATOR
Intervention: 200 mg MPA daily for surgically treated endometrial carcinoma stage I (Group II)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1000 mg MPA daily for metastasized breast cancer (Group III)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1000 mg MPA daily for metastatic breast cancer (Group IV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 50 mg MPA daily for pelvic endometriosis (Group I)
Number of subjects: 10
Study: 31601535

Group type: EXPERIMENTAL
Intervention: Slow-pull technique
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard suction technique
Number of subjects: 110
Study: 30281941

Group type: COMPARATOR
Intervention: 4 mL mometasone furoate-soaked biodegradable nasal dressings (BNDs) for 1 week
Number of subjects: 64

Group type: COMPARATOR
Intervention: 4 mL mometasone furoate-soaked biodegradable nasal dressings (BNDs) for 2 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: 8 mL mometasone furoate-soaked biodegradable nasal dressings (BNDs) for 1 week
Number of subjects: 64

Group type: COMPARATOR
Intervention: 8 mL mometasone furoate-soaked biodegradable nasal dressings (BNDs) for 2 weeks
Number of subjects: 64
Study: 28710850

Group type: EXPERIMENTAL
Intervention: BAI 80 μg/day
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: BAI 160 μg/day
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: MDI 80 μg/day
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: MDI 160 μg/day
Number of subjects: 628

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study: 26034880

Group type: EXPERIMENTAL
Intervention: Dapivirine and Maraviroc Vaginal Rings (25 mg DPV, 100 mg MVC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring (25 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Maraviroc Vaginal Ring (100 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination Ring (DPV and MVC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Single-drug Rings (DPV only, MVC only)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring
Number of subjects: 48

Group type: COMPARATOR
Intervention: All 4 rings (DPV, MVC, DPV + MVC, Placebo)
Number of subjects: 48
Study: 24204865

Group type: EXPERIMENTAL
Intervention: Placebo treatment with educational handout
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Placebo treatment without educational handout
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cold pressor-induced pain
Number of subjects: 50
Study: 21806767

Group type: EXPERIMENTAL
Intervention: Aliskiren/Amlodipine 150/5 mg, then titrated to 300/10 mg
Number of subjects: 443

Group type: COMPARATOR
Intervention: Amlodipine 5 mg, then titrated to 10 mg
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Aliskiren/Amlodipine
Number of subjects: 443

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 443
Study: 19698171

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Supportive Listening
Number of subjects: 122
Study: 16900043

Group type: EXPERIMENTAL
Intervention: Internet-based rehabilitation course (20-week program with 19 films, written material, and Socratic dialogue)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Internet-based rehabilitation course
Number of subjects: 55

Group type: COMPARATOR
Intervention: Waiting list group (control)
Number of subjects: 55
Study: 15007001

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11545288

Group type: EXPERIMENTAL
Intervention: High selenium diet (297 microg/d)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low selenium diet (13 microg/d)
Number of subjects: 11
Study: 8558934

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 10 micrograms/kg/day continuous i.v. infusion started 24 hours after chemotherapy completion.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Historical control group (no G-CSF)
Number of subjects: 26
Study: 1921252

Group type: EXPERIMENTAL
Intervention: 20 mEq/d NaCl intake
Number of subjects: 27

Group type: COMPARATOR
Intervention: 208 mEq/d NaCl intake
Number of subjects: 27
Study: 6343309

Group type: EXPERIMENTAL
Intervention: Continuous course radiotherapy (6600 rad in 30/33 fractions over 7‐8 weeks)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Split course therapy (3000 rad in 10 fractions over 2 weeks, a three‐week rest, 3000 rad in 10 fractions over 2 weeks)
Number of subjects: 141
Study: 31171491

Group type: EXPERIMENTAL
Intervention: 24-hour ankle accelerometers
Number of subjects: 101
Study: 28137295

Group type: EXPERIMENTAL
Intervention: Nivolumab or pembrolizumab (anti-PD-1 antibodies) administered according to recommended dosing schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy delivered in three fractions of 8Gy to the largest FDG-avid metastatic lesion
Number of subjects: 0
Study: 25567051

Group type: EXPERIMENTAL
Intervention: Avocado diet (AV) including one fresh Hass avocado (136 g) per day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Moderate-fat diet (MF) mainly using high oleic acid oils
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lower-fat diet (LF: 24% fat)
Number of subjects: 45
Study: 23953762

Group type: EXPERIMENTAL
Intervention: High-intensity locomotor training on a lower-body, positive-pressure treadmill for 8 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Healthy participants (control group)
Number of subjects: 13
Study: 21360405

Group type: EXPERIMENTAL
Intervention: High-intensity interval running (6 × 3 min at 90% VO(2max) with active recovery at 50% VO(2max))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Moderate-intensity continuous running (50 min at 70% VO(2max))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-intensity interval running
Number of subjects: 8

Group type: COMPARATOR
Intervention: Moderate-intensity continuous running
Number of subjects: 8